Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386157148> ?p ?o ?g. }
- W4386157148 abstract "Abstract Aims Apart from cardiotoxicity, the chemotherapeutic doxorubicin (DOX) induces vascular toxicity, represented by arterial stiffness and endothelial dysfunction. Both parameters are of interest for cardiovascular risk stratification as they are independent predictors of future cardiovascular events in the general population. However, the time course of DOX-induced cardiovascular toxicity remains unclear. Moreover, current biomarkers for cardiovascular toxicity prove insufficient. Here, we longitudinally evaluated functional and molecular markers of DOX-induced cardiovascular toxicity in a murine model. Molecular markers were further validated in patient plasma. Methods and results DOX (4 mg/kg) or saline (vehicle) was administered intra-peritoneally to young, male mice weekly for 6 weeks. In vivo cardiovascular function and ex vivo arterial stiffness and vascular reactivity were evaluated at baseline, during DOX therapy (Weeks 2 and 4) and after therapy cessation (Weeks 6, 9, and 15). Left ventricular ejection fraction (LVEF) declined from Week 4 in the DOX group. DOX increased arterial stiffness in vivo and ex vivo at Week 2, which reverted thereafter. Importantly, DOX-induced arterial stiffness preceded reduced LVEF. Further, DOX impaired endothelium-dependent vasodilation at Weeks 2 and 6, which recovered at Weeks 9 and 15. Conversely, contraction with phenylephrine was consistently higher in the DOX-treated group. Furthermore, proteomic analysis on aortic tissue identified increased thrombospondin-1 (THBS1) and alpha-1-antichymotrypsin (SERPINA3) at Weeks 2 and 6. Up-regulated THBS1 and SERPINA3 persisted during follow-up. Finally, THBS1 and SERPINA3 were quantified in plasma of patients. Cancer survivors with anthracycline-induced cardiotoxicity (AICT; LVEF < 50%) showed elevated THBS1 and SERPINA3 levels compared with age-matched control patients (LVEF ≥ 60%). Conclusions DOX increased arterial stiffness and impaired endothelial function, which both preceded reduced LVEF. Vascular dysfunction restored after DOX therapy cessation, whereas cardiac dysfunction persisted. Further, we identified SERPINA3 and THBS1 as promising biomarkers of DOX-induced cardiovascular toxicity, which were confirmed in AICT patients. Translational perspective DOX induced arterial stiffness and endothelial dysfunction, which preceded impairment of left ventricular systolic function. Hence, arterial stiffness and endothelial dysfunction represent potential early, functional markers of future cardiovascular dysfunction in patients receiving DOX. Of note, DOX-induced arterial stiffness and endothelial dysfunction were transient, highlighting the importance of timing for evaluating these vascular parameters in patients. Furthermore, anthracycline-induced cardiotoxicity patients showed elevated SERPINA3 and THBS1 in plasma, raising awareness for a role of these proteins in cardiovascular toxicity with possible diagnostic value in DOX-treated patients." @default.
- W4386157148 created "2023-08-26" @default.
- W4386157148 creator A5007564953 @default.
- W4386157148 creator A5026823145 @default.
- W4386157148 creator A5026852017 @default.
- W4386157148 creator A5032108229 @default.
- W4386157148 creator A5033644109 @default.
- W4386157148 creator A5045812576 @default.
- W4386157148 creator A5059546075 @default.
- W4386157148 creator A5059862918 @default.
- W4386157148 creator A5070291877 @default.
- W4386157148 creator A5072677920 @default.
- W4386157148 creator A5074272742 @default.
- W4386157148 creator A5076009877 @default.
- W4386157148 creator A5083699680 @default.
- W4386157148 creator A5085189931 @default.
- W4386157148 creator A5089083958 @default.
- W4386157148 date "2023-08-25" @default.
- W4386157148 modified "2023-10-14" @default.
- W4386157148 title "Doxorubicin-induced cardiovascular toxicity: a longitudinal evaluation of functional and molecular markers" @default.
- W4386157148 cites W1964757399 @default.
- W4386157148 cites W1968264871 @default.
- W4386157148 cites W2004006569 @default.
- W4386157148 cites W2015385554 @default.
- W4386157148 cites W2028438852 @default.
- W4386157148 cites W2065522670 @default.
- W4386157148 cites W2076803848 @default.
- W4386157148 cites W2087954557 @default.
- W4386157148 cites W2096320106 @default.
- W4386157148 cites W2104842795 @default.
- W4386157148 cites W2108824630 @default.
- W4386157148 cites W2110737689 @default.
- W4386157148 cites W2111972252 @default.
- W4386157148 cites W2113842550 @default.
- W4386157148 cites W2114738305 @default.
- W4386157148 cites W2120435538 @default.
- W4386157148 cites W2131258412 @default.
- W4386157148 cites W2138043196 @default.
- W4386157148 cites W2140182328 @default.
- W4386157148 cites W2143176508 @default.
- W4386157148 cites W2144120465 @default.
- W4386157148 cites W2161776889 @default.
- W4386157148 cites W2161841978 @default.
- W4386157148 cites W2170548844 @default.
- W4386157148 cites W2171204543 @default.
- W4386157148 cites W2326762688 @default.
- W4386157148 cites W2327880094 @default.
- W4386157148 cites W2416206801 @default.
- W4386157148 cites W2549628735 @default.
- W4386157148 cites W2586749137 @default.
- W4386157148 cites W2736344646 @default.
- W4386157148 cites W2753972973 @default.
- W4386157148 cites W2766261199 @default.
- W4386157148 cites W2769708180 @default.
- W4386157148 cites W2784666693 @default.
- W4386157148 cites W2807970119 @default.
- W4386157148 cites W2837634082 @default.
- W4386157148 cites W2889011659 @default.
- W4386157148 cites W2920032678 @default.
- W4386157148 cites W2968129642 @default.
- W4386157148 cites W3001273413 @default.
- W4386157148 cites W3015394081 @default.
- W4386157148 cites W3096174844 @default.
- W4386157148 cites W3132937541 @default.
- W4386157148 cites W3157267764 @default.
- W4386157148 cites W3161508771 @default.
- W4386157148 cites W3197052160 @default.
- W4386157148 cites W3208337367 @default.
- W4386157148 cites W3210432984 @default.
- W4386157148 cites W3217241629 @default.
- W4386157148 cites W4200606180 @default.
- W4386157148 cites W4205831557 @default.
- W4386157148 cites W4280582719 @default.
- W4386157148 cites W4283819997 @default.
- W4386157148 cites W4293217929 @default.
- W4386157148 cites W4306247167 @default.
- W4386157148 cites W4313826313 @default.
- W4386157148 doi "https://doi.org/10.1093/cvr/cvad136" @default.
- W4386157148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37625456" @default.
- W4386157148 hasPublicationYear "2023" @default.
- W4386157148 type Work @default.
- W4386157148 citedByCount "0" @default.
- W4386157148 crossrefType "journal-article" @default.
- W4386157148 hasAuthorship W4386157148A5007564953 @default.
- W4386157148 hasAuthorship W4386157148A5026823145 @default.
- W4386157148 hasAuthorship W4386157148A5026852017 @default.
- W4386157148 hasAuthorship W4386157148A5032108229 @default.
- W4386157148 hasAuthorship W4386157148A5033644109 @default.
- W4386157148 hasAuthorship W4386157148A5045812576 @default.
- W4386157148 hasAuthorship W4386157148A5059546075 @default.
- W4386157148 hasAuthorship W4386157148A5059862918 @default.
- W4386157148 hasAuthorship W4386157148A5070291877 @default.
- W4386157148 hasAuthorship W4386157148A5072677920 @default.
- W4386157148 hasAuthorship W4386157148A5074272742 @default.
- W4386157148 hasAuthorship W4386157148A5076009877 @default.
- W4386157148 hasAuthorship W4386157148A5083699680 @default.
- W4386157148 hasAuthorship W4386157148A5085189931 @default.
- W4386157148 hasAuthorship W4386157148A5089083958 @default.
- W4386157148 hasBestOaLocation W43861571481 @default.
- W4386157148 hasConcept C121608353 @default.